<DOC>
	<DOC>NCT01349842</DOC>
	<brief_summary>Evaluation of the use of Circulating tumour Cells to guide chemotherapy from the 3rd line of chemotherapy for metastatic breast cancer.</brief_summary>
	<brief_title>Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer</brief_title>
	<detailed_description>Phase III multicentre, randomized, open-label study comparing early evaluation of the efficacy of chemotherapy by determination of circulating tumour cells versus conventional clinical and radiological evaluation.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells, Circulating</mesh_term>
	<criteria>Women over the age of 18 years. WHO performance status: 0 to 4. Metastatic breast cancer. Progression after 2 lines of chemotherapy with decision to initiate thirdline chemotherapy. Disease evaluable by CTC (CTCpositive before starting chemotherapy). Histology: lobular or ductal adenocarcinoma. Information of the patient and signature of the informed consent form by the patient or her legal representative. Disease not evaluable by CTC (CTCnegative before starting chemotherapy). History of other potentially metastatic cancer (stage III or IV cancer) different from breast cancer. Histology other than lobular or ductal adenocarcinoma. Pregnant woman, women likely to become pregnant or nursing mothers. Persons deprived of their freedom or under guardianship. Women unable to comply with the medical followup of the study for geographical, social or mental reasons.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>